GURU.Markets stock price, segment price, and overall market index valuation
The company's share price AstraZeneca PLC
AstraZeneca's share price reflects the success of its research and development division. The company, a leader in the global pharmaceutical industry, is growing thanks to a strong portfolio of drugs in oncology, cardiology, and respiratory diseases. This is a bet on innovation in medicine.
Share prices of companies in the market segment - Pharma holding
AstraZeneca is a global biopharmaceutical company with key segments in oncology, rare disease treatment, and cardiovascular disease. We classify it as a Pharma Holding, and the chart below shows the overall performance of the entire large drug manufacturing industry.
Broad Market Index - GURU.Markets
AstraZeneca is a global biopharmaceutical company with a strong portfolio of drugs in oncology, cardiology, and respiratory diseases. Its significant market capitalization earns it a prominent place in the GURU.Markets index. The chart below represents the entire market. Find out how AZN compares to it.
Change in the price of a company, segment, and market as a whole per day
AZN - Daily change in the company's share price AstraZeneca PLC
For AstraZeneca, a major biopharmaceutical company, daily price changes are a measure of its response to clinical trial results. The graph of these fluctuations is unspectacular, but they are an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma holding
AstraZeneca is a leader in the global pharmaceutical industry. This chart reflects the average daily volatility of the entire sector. It serves as a benchmark for comparing the company's robust oncology portfolio to what extent it is more or less stable than an industry prone to clinical trial news.
Daily change in the price of a broad market stock, index - GURU.Markets
AstraZeneca is a major British-Swedish biopharmaceutical company. The pharmaceutical sector may operate by its own rules, but shares of such giants are still subject to overall market trends. The chart below shows overall market volatility, providing context for assessing AstraZeneca's performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization AstraZeneca PLC
AstraZeneca has demonstrated strong growth over the past year thanks to its oncology and rare disease portfolio. The company has successfully transitioned away from its reliance on its COVID-19 vaccine. The chart below shows how investors viewed the strength of its R&D and commercial success.
Annual dynamics of market capitalization of the market segment - Pharma holding
AstraZeneca, the British-Swedish pharmaceutical giant, has made a name for itself with a strong portfolio of drugs in oncology and rare diseases. Its focus on innovative and high-margin segments often allows the company to grow faster than the pharmaceutical sector average. The chart clearly demonstrates the effectiveness of this R&D strategy.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
AstraZeneca is a global biopharmaceutical company whose growth is driven by a portfolio of innovative drugs, particularly in oncology. Its performance is less dependent on economic cycles but highly sensitive to clinical trial results and regulatory approvals. A comparison with the market demonstrates how a scientific breakthrough can create value regardless of economic conditions.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization AstraZeneca PLC
AstraZeneca's value, like that of other large pharmaceutical companies, is determined by the life cycle of its drugs. Monthly fluctuations on the chart reflect news about clinical trial results, regulatory approvals for new drugs, and sales data in key therapeutic areas, such as oncology.
Monthly dynamics of market capitalization of the market segment - Pharma holding
This shows the dynamics of the entire pharmaceutical sector, where AstraZeneca is a key innovator. Its movements reflect overall investment in R&D and demand for new drugs. This is the backdrop against which AstraZeneca, particularly in oncology, has demonstrated outperforming growth.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
This chart reflects overall market sentiment. For AstraZeneca, a major pharmaceutical company, this is the backdrop. Its movements are typically less volatile than the market, demonstrating the defensive nature of its business, based on patented drugs and stable cash flows.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization AstraZeneca PLC
AstraZeneca, the British-Swedish pharmaceutical company, sees its shares fluctuate weekly based on news about clinical trials, particularly in oncology, and regulatory decisions around the world. This chart shows the market's reaction to scientific breakthroughs and the commercial prospects of its drug portfolio.
Weekly dynamics of market capitalization of the market segment - Pharma holding
AstraZeneca, as an innovative pharmaceutical company, often outperforms its sector thanks to breakthroughs in oncology and other areas. While the industry may stagnate, positive clinical trial data can propel AZN shares ahead of their competitors. The chart provides a clear indication of the innovation premium the market is valuing.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
AstraZeneca is a global pharmaceutical company. Big pharma stocks are typically considered defensive because demand for their medications is stable. This chart will help test whether this is true: do AstraZeneca's weekly price movements actually smooth out overall market volatility?
Market capitalization of the company, segment and market as a whole
AZN - Market capitalization of the company AstraZeneca PLC
AstraZeneca's market capitalization chart is a story of successful scientific breakthroughs and transformation. Its share price growth in recent years reflects market recognition of its strong portfolio of oncology drugs and other blockbusters. Investors highly value the productivity of its R&D division, which has transformed the company into a leader in global pharmaceuticals.
AZN - Share of the company's market capitalization AstraZeneca PLC within the market segment - Pharma holding
AstraZeneca, the Anglo-Swedish pharmaceutical giant, holds a prominent position in the sector thanks to its strong portfolio of oncology and cardiology drugs. Its significant market share reflects its success in developing innovative drugs, making it a key player in the global pharmaceutical industry.
Market capitalization of the market segment - Pharma holding
This chart shows the trillion-dollar value of the global pharmaceutical industry. AstraZeneca is one of its leaders, particularly strong in oncology. The dynamics of the entire sector's market capitalization that you see are largely determined by advances in the development of new breakthrough drugs, and AstraZeneca is at the forefront of this research.
Market capitalization of all companies included in a broad market index - GURU.Markets
AstraZeneca is a British-Swedish pharmaceutical giant that plays a key role in the development of innovative medicines. Its market capitalization reflects the value of its drug portfolio and research and development. The chart below shows the significant market share a single successful pharmaceutical company can command.
Book value capitalization of the company, segment and market as a whole
AZN - Book value capitalization of the company AstraZeneca PLC
AstraZeneca's material foundation is its cutting-edge research and development centers, high-tech biopharmaceutical manufacturing facilities, and a valuable portfolio of drug patents. The chart below is a financial reflection of its successful R&D strategy, with each approved blockbuster significantly strengthening the company's asset base.
AZN - Share of the company's book capitalization AstraZeneca PLC within the market segment - Pharma holding
American Express serves the premium segment, and its infrastructure matches its status. The chart shows the company's share of physical assets in the payments industry: not only data centers, but also exclusive airport lounges and offices in prestigious locations. It's the tangible embodiment of elite status.
Market segment balance sheet capitalization - Pharma holding
Pharmaceuticals is a capital-intensive sector, as the chart illustrates. AstraZeneca is betting on knowledge-intensive capital. Its main assets are not so much its factories as its patent portfolio and cutting-edge R&D centers, where innovative drugs are created that will shape the future of medicine.
Book value of all companies included in the broad market index - GURU.Markets
AstraZeneca is at the forefront of biopharmaceuticals. Its book value is derived from its global network of research centers and high-tech manufacturing facilities. This is real capital that the company invests in developing drugs for cancer and other serious diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - AstraZeneca PLC
AstraZeneca's book value is derived from its factories and R&D centers. Its market capitalization is significantly higher thanks to its strong pipeline of drugs in oncology and other high-growth areas. The chart shows the premium the market is paying for its successful scientific developments and future growth.
Market to book capitalization ratio in a market segment - Pharma holding
AstraZeneca is a British-Swedish pharmaceutical company with a strong portfolio in oncology and rare diseases. Its value is determined by the potential of its scientific developments and future drug sales. This chart shows the premium investors pay for innovation in its R&D pipeline, which significantly exceeds the value of its physical production assets.
Market to book capitalization ratio for the market as a whole
AstraZeneca is a global biopharmaceutical company that has strengthened its position thanks to successful developments in oncology and the COVID-19 vaccine. This chart reflects the average market valuation of the company. Against this backdrop, AstraZeneca's premium reflects how investors value its scientific potential and growing portfolio of innovative drugs.
Debts of the company, segment and market as a whole
AZN - Company debts AstraZeneca PLC
For pharmaceutical giant AstraZeneca, debt is a crucial tool for funding growth, particularly in oncology. The company actively uses debt to conduct expensive clinical trials and for strategic acquisitions that expand its drug portfolio. This chart shows how leverage supports its scientific and commercial ambitions.
Market segment debts - Pharma holding
AstraZeneca, the British-Swedish pharmaceutical giant, is actively investing in the development of innovative drugs. Acquisitions, such as the purchase of Alexion, which was financed in part with debt, are a key part of its growth strategy. This chart shows how the company uses debt to strengthen its drug portfolio and competitive position.
Market debt in general
AstraZeneca is a British-Swedish pharmaceutical company that has achieved significant success in oncology and other fields. Success in the pharmaceutical industry requires sustained, substantial investments in research. This chart shows the overall picture of corporate debt, which helps assess how aggressively AstraZeneca uses financial leverage to fund its development.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio AstraZeneca PLC
AstraZeneca is one of the world's leading pharmaceutical companies, placing large bets on oncology and vaccines. This chart shows how the company uses debt to finance major acquisitions, such as Alexion, to strengthen its rare disease portfolio. High debt reflects its aggressive growth strategy and the risks that come with it.
Market segment debt to market segment book capitalization - Pharma holding
AstraZeneca is a leading biopharmaceutical company active in areas such as oncology and rare diseases. Developing innovative drugs requires significant investment. This chart shows how the company funds its research. It compares its debt to the market capitalization of the pharmaceutical industry, reflecting its growth strategy and risk appetite.
Debt to book value of all companies in the market
AstraZeneca, like other large pharmaceutical companies, finances expensive research and acquisitions to expand its drug portfolio. This chart allows us to assess its strategy against the backdrop of the overall economy. It shows how the company's debt policy differs from the average debt level of all publicly traded companies.
P/E of the company, segment and market as a whole
P/E - AstraZeneca PLC
This chart shows the market valuation of AstraZeneca, a global biopharmaceutical company. Its P/E is directly linked to the success of its drugs, particularly in oncology. The dynamics of this ratio demonstrate investor confidence in the company's research potential and its ability to bring new, in-demand drugs to market.
P/E of the market segment - Pharma holding
AstraZeneca is a global biopharmaceutical company with a strong pipeline of drugs in oncology, cardiology, and respiratory diseases. The company is rapidly growing through innovation. This chart reflects the average valuation for the pharmaceutical industry. It serves as an indicator of how much expectations for AstraZeneca's future blockbusters are above or below the industry average.
P/E of the market as a whole
AstraZeneca is a global biopharmaceutical company with a strong pipeline of drugs in oncology, cardiology, and respiratory diseases. Its valuation, like that of other large pharmaceutical companies, is less dependent on the short-term economic cycles illustrated here. Clinical trial results and the successful launch of new blockbuster drugs are far more important.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company AstraZeneca PLC
AstraZeneca is a global biopharmaceutical company with a strong portfolio in oncology, cardiology, and respiratory diseases. This chart reflects investor expectations for its R&D pipeline and the commercialization of new drugs. The company's valuation depends on sales forecasts for its key drugs and the market's confidence in AstraZeneca's ability to bring new blockbusters to market.
%20P%2FE%20AstraZeneca%20PLC&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-AstraZeneca-PLC&v=1772477987609 "Chart of the company's future (projected) P/E AstraZeneca PLC")
Future (projected) P/E of the market segment - Pharma holding
AstraZeneca, a British-Swedish biopharmaceutical company, has a strong pipeline of drugs in oncology, cardiology, and respiratory diseases. This chart shows the market's valuation of its research and development pipeline. Comparing AZN's profit forecasts with the sector's overall performance demonstrates how confident investors are in the future success of its new drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-holding&v=1772477987609 "Future (projected) P/E graph of the market segment - Pharma holding")
Future (projected) P/E of the market as a whole
AstraZeneca is a global biopharmaceutical company that has achieved significant success in oncology and rare diseases. The pharmaceutical sector often moves independently of the broader market, reacting to trial results. However, the overall market backdrop, as shown by this chart, influences the valuation of the entire industry and investor appetite for healthcare stocks.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772477987610 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit AstraZeneca PLC
AstraZeneca is a global biopharmaceutical company focused on developing medicines in areas such as oncology, cardiology, and respiratory diseases. The company's profits are directly dependent on the success of its research and its ability to bring new blockbuster drugs to market. This chart illustrates the financial impact of these scientific advances.
Profit of companies in the market segment - Pharma holding
AstraZeneca is a global biopharmaceutical company with significant advances in oncology and other therapeutic areas. Its focus on innovative medicines allows it to generate high profits and set new standards of care. The success of its developments is a key factor in determining the overall profitability and direction of the pharmaceutical industry.
Overall market profit
AstraZeneca is a global biopharmaceutical company focused on developing innovative medicines in areas such as oncology, cardiology, and respiratory diseases. Successful clinical trials and the launch of new drugs ensure the company's long-term growth and high profitability, making it a key player in the healthcare sector, a pillar of the economy.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company AstraZeneca PLC
AstraZeneca is one of the world's leading biopharmaceutical companies. This chart reflects analysts' expectations for sales of its drug portfolio, particularly in oncology. Successful clinical trials and the launch of new drugs are the primary drivers for future profit forecasts.
%20profit%20of%20the%20company%20AstraZeneca%20PLC&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-AstraZeneca-PLC&v=1772477987612 "Graph of future (projected) profit of the company AstraZeneca PLC")
Future (predicted) profit of companies in the market segment - Pharma holding
AstraZeneca is a global biopharmaceutical company with a strong pipeline of drugs in oncology, cardiology, and respiratory diseases. The data presented illustrates profitability forecasts for the entire pharmaceutical industry, allowing one to assess how AstraZeneca's innovative pipeline and strategic acquisitions impact the company's growth potential.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-holding&v=1772477987616 "Graph of future (predicted) profits of companies in a market segment - Pharma holding")
Future (predicted) profit of the market as a whole
The trajectory on this chart illustrates expectations for one of the world's largest pharmaceutical giants. AstraZeneca's profit forecast depends on sales of its blockbuster drugs in oncology, cardiology, and respiratory diseases, as well as the results of clinical trials of new drugs. Success in bringing innovative drugs to market determines long-term growth.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772477987618 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - AstraZeneca PLC
AstraZeneca is a global biopharmaceutical company with a strong pipeline of drugs in oncology and other areas. This chart shows the market's valuation of its current and future revenue. A high multiple often indicates investor optimism about its product portfolio and the potential for new developments.
P/S market segment - Pharma holding
AstraZeneca is a global biopharmaceutical company with a strong pipeline of drugs in oncology, cardiology, and respiratory diseases. This chart shows the average revenue estimate in the pharmaceutical industry. It provides insight into the premium investors are willing to pay for successful clinical trials and the potential of the company's new drugs.
P/S of the market as a whole
AstraZeneca is a global biopharmaceutical company with a strong portfolio in oncology and rare diseases. Its revenue is growing thanks to innovative drugs. This chart shows the average revenue estimate for the market. For AstraZeneca, it helps understand how highly investors value its scientific potential and ability to bring new, successful drugs to market.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company AstraZeneca PLC
AstraZeneca is a global biopharmaceutical company with a strong pipeline of drugs in oncology, cardiology, and respiratory diseases. Its future revenue estimates are based on sales forecasts for existing drugs and the potential of new developments. This chart reflects investor confidence in the company's R&D pipeline and its ability to successfully bring new blockbusters to market.
%20P%2FS%20AstraZeneca%20PLC&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-AstraZeneca-PLC&v=1772477987620 "The graph of the company's future (projected) P/S AstraZeneca PLC")
Future (projected) P/S of the market segment - Pharma holding
AstraZeneca is a British-Swedish pharmaceutical company with a strong pipeline of oncology and rare disease drugs. This chart compares its future sales expectations with those of other pharmaceutical industry players. How highly does the market value its scientific developments and the potential of its new drugs to drive long-term growth?
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20holding&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-holding&v=1772477987622 "Future (projected) P/S market segment graph - Pharma holding")
Future (projected) P/S of the market as a whole
AstraZeneca is a global biopharmaceutical company with significant success in oncology and other therapeutic areas. Its growth forecasts, based on a strong pipeline, contribute significantly to investor optimism regarding the entire healthcare sector. This optimism is part of the overall expectations illustrated by this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772477987623 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales AstraZeneca PLC
AstraZeneca is a global biopharmaceutical company focused on developing innovative medicines in oncology, cardiology, and respiratory diseases. This chart demonstrates the commercial success of its product portfolio and the demand for its medicines from healthcare systems worldwide.
Sales of companies in the market segment - Pharma holding
AstraZeneca is a global biopharmaceutical company focused on developing innovative medicines in oncology, cardiology, and respiratory diseases. Its growth depends on successful clinical trials. This chart shows overall pharmaceutical sales, giving an idea of the market size and competition AstraZeneca faces.
Overall market sales
AstraZeneca is a global biopharmaceutical company focused on developing innovative medicines in areas such as oncology and cardiology. Its growth is driven by successful research and development. This overall economic activity chart for AstraZeneca is indirectly important because it impacts the ability of healthcare systems around the world to finance the purchase of its drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company AstraZeneca PLC
AstraZeneca is a global biopharmaceutical company focused on oncology, cardiovascular, and respiratory diseases. Its future revenue growth depends on sales of existing blockbusters and approvals of new drugs. This chart shows how analysts assess the commercial potential of its drug portfolio and clinical trial results.
%20sales%20of%20the%20company%20AstraZeneca%20PLC&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-AstraZeneca-PLC&v=1772477987626 "Schedule of future (projected) sales of the company AstraZeneca PLC")
Future (projected) sales of companies in the market segment - Pharma holding
AstraZeneca is a global biopharmaceutical company focused on developing innovative medicines in oncology, cardiology, and respiratory diseases. This chart shows projected revenues for the entire pharmaceutical sector. It provides insight into overall healthcare spending trends, which is important context for evaluating AstraZeneca's pipeline.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-holding&v=1772477987627 "Schedule of future (projected) sales of companies in the market segment - Pharma holding")
Future (projected) sales of the market as a whole
AstraZeneca is a global biopharmaceutical company focused on developing innovative medicines. Demand for its chronic disease treatments is stable, but the overall economic environment matters. This chart helps assess the ability of healthcare systems around the world to finance the purchase of expensive medications. Countries' economic growth directly impacts their healthcare budgets.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772477987628 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality AstraZeneca PLC
AstraZeneca is a global biopharmaceutical company focused on developing innovative medicines in oncology, cardiology, and respiratory diseases. This indicator reflects the return on its proprietary drug portfolio. Successful clinical trials and the launch of new blockbusters directly impact financial performance.
Market segment marginality - Pharma holding
AstraZeneca is a global biopharmaceutical company with a strong pipeline of drugs in oncology, cardiology, and respiratory diseases. Successful research and development of new drugs is the primary driver of its growth and profitability. This metric demonstrates how innovative, patent-protected products enable the company to maintain profitability above the industry average.
Market marginality as a whole
AstraZeneca is a global biopharmaceutical company focused on innovative medicines in oncology and rare diseases. This chart shows overall profitability. It demonstrates how successful scientific research and a portfolio of patented medicines can drive growth and profitability significantly above the national average.
Employees in the company, segment and market as a whole
Number of employees in the company AstraZeneca PLC
AstraZeneca is a global biopharmaceutical company with a strong pipeline of drugs in oncology, cardiology, and respiratory diseases. This chart shows the size of its research and commercial teams. This growth is directly related to successful clinical trials, acquisitions, and the global launch of new breakthrough drugs.
Share of the company's employees AstraZeneca PLC within the market segment - Pharma holding
This figure demonstrates AstraZeneca's standing as a leader in the global pharmaceutical industry. The company's significant workforce in the sector, particularly in R&D, underscores its commitment to scientific innovation. This human capital underpins the development of breakthrough drugs in oncology, cardiology, and respiratory diseases.
Number of employees in the market segment - Pharma holding
AstraZeneca is a British-Swedish pharmaceutical company that has become world-renowned for its vaccine. Its strength lies in its research and development, which requires thousands of scientists. This chart illustrates the research-intensive nature of the pharmaceutical sector, where AstraZeneca is one of the world's leading centers for the development of innovative drugs and vaccines.
Number of employees in the market as a whole
AstraZeneca is a British-Swedish biopharmaceutical company known for its strong positions in oncology, rare disease treatments, and, of course, its vaccine. This chart reflects the state of the global economy, which supports healthcare systems. Stable employment and GDP growth allow governments and insurance companies to allocate funds to purchase the innovative and expensive drugs being developed by AZN.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company AstraZeneca PLC (AZN)
AstraZeneca is an innovative biopharmaceutical company. Its value is determined by its portfolio of patented drugs and promising developments. Like other industry leaders, its high market valuation per employee reflects the enormous value of the intellectual property created by its scientists.
%20of%20the%20company%20AstraZeneca%20PLC%20(AZN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-AstraZeneca-PLC-AZN&v=1772477987633 "Chart of market capitalization per employee (in thousands of dollars) of the company AstraZeneca PLC (AZN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma holding
AstraZeneca has successfully transformed itself into a leader in oncology and biopharmaceuticals. Its value, like that of other pharma giants, lies in its R&D pipeline and patents. This chart visualizes the success of this strategy, showing the high market value the market assigns to each employee working on the next blockbuster.
%20by%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-holding&v=1772477987633 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma holding")
Market capitalization per employee (in thousands of dollars) for the overall market
AstraZeneca is a British-Swedish pharmaceutical company that has made breakthroughs in oncology and other fields. The high market capitalization per employee, illustrated by this chart, is driven by a portfolio of successful patented drugs. Each scientist and researcher contributes to the creation of intellectual property worth billions of dollars.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772477987635 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company AstraZeneca PLC (AZN)
AstraZeneca is a British-Swedish pharmaceutical giant known for its vaccine and strong oncology portfolio. Like Eli Lilly, it's an R&D and patent-based company. This chart shows how successful their research and development efforts are. Each successful drug launched on the market recoups its R&D costs many times over and provides high returns per employee.
%20Chart%20AstraZeneca%20PLC%20(AZN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-AstraZeneca-PLC-AZN&v=1772477987636 "Company Profit Per Employee (in thousands of dollars) Chart AstraZeneca PLC (AZN)")
Profit per employee (in thousands of dollars) in the market segment - Pharma holding
AstraZeneca is a global biopharmaceutical company. This chart shows the average for the entire pharmaceutical industry. This sector is a "blockbuster business." The average return on personnel is high because R&D (the creation of patents) generates high profits, which cover all the costs of the thousands of scientists working on future drugs.
%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-holding&v=1772477987636 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma holding")
Profit per employee (in thousands of dollars) for the market as a whole
AstraZeneca is a British-Swedish biopharmaceutical company actively working on the development of innovative medicines, including in oncology. Like other pharmaceutical giants, its profitability is determined by the success of its R&D. This metric demonstrates how investment in science enables the creation of products that deliver a high financial return per scientist and employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772477987637 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee AstraZeneca PLC (AZN)
AstraZeneca is a global biopharmaceutical company known for its developments in oncology and other fields. This chart reflects a business model where investments in research lead to the creation of patented drugs. High revenue per employee is the result of the successful commercialization of scientific discoveries by a small R&D team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-AstraZeneca-PLC-AZN&v=1772477987637 "Sales chart per company employee AstraZeneca PLC (AZN)")
Sales per employee in the market segment - Pharma holding
AstraZeneca is a global biopharmaceutical company with a strong portfolio in oncology and rare diseases. This chart compares revenue per employee to the segment average. It demonstrates how effectively the company translates its successful R&D into sales using its own employees compared to other pharma giants.
Sales per employee for the market as a whole
AstraZeneca is a British-Swedish biopharmaceutical company that has made breakthroughs in oncology. Like other "big pharma" companies, their performance is determined by the success of R&D. This chart shows how their patented drug portfolio generates revenue, which is then reinvested in the search for new blockbusters. It's a high-risk business, but also one with a high return on capital.
Short shares by company, segment and market as a whole
Shares shorted by company AstraZeneca PLC (AZN)
AstraZeneca is a British-Swedish pharmaceutical company with a strong portfolio in oncology and rare diseases. The bearish sentiment seen in this chart may be related to concerns about competition. Investors may be betting that competitors' new drugs will be more effective or that the company will experience setbacks in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-AstraZeneca-PLC-AZN&v=1772477987642 "Short Shares Chart for the Company AstraZeneca PLC (AZN)")
Shares shorted by market segment - Pharma holding
AstraZeneca is a British-Swedish pharmaceutical giant with strong positions in oncology, cardiology, and respiratory diseases, also renowned for its vaccine. This chart shows the general sentiment toward "big pharma." It reflects the overall bets that the sector will face stricter drug price regulations or problems in its R&D pipelines.
Shares shorted by the overall market
AstraZeneca is a global pharmaceutical company with a strong portfolio in oncology and rare diseases. Demand for its life-saving medications is unaffected by the economic outlook. This chart shows the overall level of fear. During periods of panic, investors seek "safety" in non-cyclical sectors, making AstraZeneca an attractive asset.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator AstraZeneca PLC (AZN)
AstraZeneca, a major pharmaceutical company with a strong oncology portfolio, could see this indicator rise above 70 on the back of successful clinical trials or strong sales. A drop below 30 could be caused by concerns about research failures or increased competition for key drugs.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-AstraZeneca-PLC-AZN&v=1772477987649 "RSI 14 indicator chart for the company's stock AstraZeneca PLC (AZN)")
RSI 14 Market Segment - Pharma holding
AstraZeneca (AZN) is a British-Swedish pharmaceutical giant that has made an impressive comeback, becoming a leader in oncology drug development. This metric measures the "temperature" of the entire pharmaceutical sector. It helps us understand whether AZN's growth is a result of its unique R&D success, or whether the entire sector is overheated by a wave of innovation.
RSI 14 for the overall market
AstraZeneca is a British-Swedish pharmaceutical giant with a strong portfolio in oncology, cardiology, and respiratory diseases. The company has placed a strong emphasis on innovation. This chart shows how the overall market environment—whether panic or euphoria—influences the perception of this stable yet science-intensive business, which typically operates in its own discovery cycle.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AZN (AstraZeneca PLC)
This chart shows the collective opinion on AstraZeneca. When setting their target price, analysts focus on its strong oncology portfolio (Tagrisso, Imfinzi) and new blockbusters. Their forecasts are a bet that a strong R&D pipeline and successful acquisitions will allow the company to offset future patent cliffs and outperform the sector.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AZN-AstraZeneca-PLC&v=1772477987652 "A chart showing analyst consensus forecasts for the expected stock price. AZN (AstraZeneca PLC)")
The difference between the consensus estimate and the actual stock price AZN (AstraZeneca PLC)
AstraZeneca is a British-Swedish biopharmaceutical company with a strong pipeline of drugs in oncology, cardiology, and respiratory diseases. This chart shows the difference between analysts' target price and the current price. It illustrates whether experts believe the company's R&D pipeline (including advances in cancer treatment) will drive growth that the market has not yet fully appreciated.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AZN-AstraZeneca-PLC&v=1772477987653 "A chart showing the difference between the consensus forecast and the actual stock price. AZN (AstraZeneca PLC)")
Analyst consensus forecast for stock prices by market segment - Pharma holding
AstraZeneca is a British-Swedish biopharmaceutical company that has made breakthroughs in oncology and rare diseases. This chart shows analysts' overall expectations for the pharmaceutical sector. It helps understand whether industry experts see potential for new blockbusters or believe the sector has exhausted its growth drivers.
Analysts' consensus forecast for the overall market share price
AstraZeneca is a global pharmaceutical giant with a strong presence in oncology. Healthcare is a defensive sector, but AZN's valuation, like Eli Lilly's, depends on the success of its R&D. This chart shows the overall consensus forecast for the market. It reflects risk appetite. In a bull market, investors are willing to pay for future drugs; in a bear market, they are not.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index AstraZeneca PLC
AstraZeneca is an Anglo-Swedish pharmaceutical giant with one of the strongest R&D pipelines in the industry, particularly in oncology (cancer treatment). This chart reflects the market's valuation of their future revenue. It represents a weighted valuation of their current blockbusters and investor confidence that their research and development will yield new breakthrough drugs.
AKIMA Market Segment Index - Pharma holding
AstraZeneca is a global biopharmaceutical company with a strong portfolio in oncology, cardiology, and rare diseases. This composite metric evaluates companies. The chart shows the average value for the segment. It helps investors understand the extent to which AZN's product portfolio and R&D pipeline enable it to outperform the average pharma company.
The AKIM Index for the overall market
AstraZeneca is a British-Swedish biopharmaceutical company with a strong portfolio in oncology, cardiology, and respiratory diseases. The company is rapidly growing thanks to innovative drugs. This chart, reflecting the market average, provides macro context. It helps assess how AstraZeneca's drug development success compares to overall economic conditions, which typically have less of an impact on the healthcare sector.
